185 related articles for article (PubMed ID: 29729809)
1. Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
Payne JF; Clark WL; Bruce BB; Wykoff CC; Brown DM; Menke BM; Iverson SM; Allen KF; Boyer DS;
Ophthalmology; 2018 Aug; 125(8):1304-1306. PubMed ID: 29729809
[No Abstract] [Full Text] [Related]
2. Ranibizumab in Diabetic Retinopathy with or without Diabetic Macular Edema.
Antoszyk AN; Tarnowski KW; Basu K; Ehrlich JS; Haskova Z
Ophthalmol Retina; 2020 Oct; 4(10):1034-1036. PubMed ID: 32512056
[No Abstract] [Full Text] [Related]
3. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
[TBL] [Abstract][Full Text] [Related]
4. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA.
Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S
Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
[TBL] [Abstract][Full Text] [Related]
6. Refractive changes after intravitreal ranibizumab injections for diabetic macular oedema.
Chatziralli I; Chatzipantelis A; Dimitriou E; Mpourouki E; Theodossiadis G; Theodossiadis P
Clin Exp Optom; 2018 May; 101(3):397-399. PubMed ID: 29134696
[TBL] [Abstract][Full Text] [Related]
7. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
8. Short-term effects of intravitreal ranibizumab therapy on diabetic macular edema.
Minami Y; Nagaoka T; Ishibazawa A; Yoshida A
BMC Ophthalmol; 2017 Mar; 17(1):28. PubMed ID: 28292270
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab treatment improves diabetic macular oedema without influencing retinal oximetry parameters.
Takasago Y; Fujita T; Nakano Y; Osaka R; Miyake M; Muraoka Y; Tsujikawa A
Acta Ophthalmol; 2019 Dec; 97(8):e1048-e1053. PubMed ID: 31127694
[TBL] [Abstract][Full Text] [Related]
10. Real-world experiences with intravitreal treatment with ranibizumab and aflibercept for diabetic macular oedema 2008-2021.
Lindboe JB; Brynskov T; Sørensen TL; Schmidt Laugesen C
Acta Ophthalmol; 2024 Jun; 102(4):e661-e662. PubMed ID: 38525896
[No Abstract] [Full Text] [Related]
11. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
[TBL] [Abstract][Full Text] [Related]
12. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
[TBL] [Abstract][Full Text] [Related]
13. Visual and Anatomic Outcomes in Patients with Diabetic Macular Edema with Limited Initial Anatomic Response to Ranibizumab in RIDE and RISE.
Pieramici DJ; Wang PW; Ding B; Gune S
Ophthalmology; 2016 Jun; 123(6):1345-50. PubMed ID: 26992841
[TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial.
Călugăru D; Călugăru M
Ophthalmic Surg Lasers Imaging Retina; 2018 Mar; 49(3):160. PubMed ID: 29554381
[No Abstract] [Full Text] [Related]
15. INVICTUS: intravitreal anti-VEGF and dexamethasone implant comparison for the treatment of diabetic macular edema: a 6 months follow-up Study.
Comet A; Gascon P; Sauvan L; Donnadieu B; Matonti F
Acta Ophthalmol; 2019 Sep; 97(6):e937-e938. PubMed ID: 30741468
[No Abstract] [Full Text] [Related]
16. Comparison of Ranibizumab 0.5 mg Versus 1.0 mg for the Treatment of Patients With Clinically Significant Diabetic Macular Edema: A Randomized, Clinical Trial.
Ferrone PJ; Jonisch J
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):536-43. PubMed ID: 27327283
[TBL] [Abstract][Full Text] [Related]
17. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Bevacizumab and Ranibizumab Injections for Diabetic Macular Edema in Medicare Beneficiaries.
Wu CM; Wu AM; Greenberg PB; Yu F; Lum F; Coleman AL
Ophthalmic Surg Lasers Imaging Retina; 2018 Apr; 49(4):241-244. PubMed ID: 29664980
[TBL] [Abstract][Full Text] [Related]
19. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
[TBL] [Abstract][Full Text] [Related]
20. LONG-TIME OUTCOME IN PATIENTS TREATED WITH RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: A 4-Year Study.
Epstein D; Amrén U
Retina; 2018 Jan; 38(1):183-186. PubMed ID: 28323678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
